KOL Health

KOL Privacy Policy

Privacy Policy

This privacy policy sets out how KOL Health, Inc. uses and protects any information that you give KOL Health, Inc. when you use this website.

KOL Health, Inc. is committed to ensuring that your privacy is protected. Should we ask you to provide certain information by which you can be identified when using this website, then you can be assured that it will only be used in accordance with this privacy statement.

KOL Health, Inc. may change this policy from time to time by updating this page. You should check this page from time to time to ensure that you are happy with any changes. This policy is effective from August 14, 2009.

What we collect:

We may collect the following information:

• Name and job title • Contact information including mailing address, email address and telephone numbers • Other information relevant to customer surveys and /or offers.

What we do with the information we gather:

• Record keeping • We may use the information to improve our products and services • We may contact you by email, phone, fax or mail. We may use the information to customize the website according to your interests.

Security:

We are committed to ensuring that your information is secure. In order to prevent unauthorized access of disclosure we have put in place suitable physical, electronic and managerial procedures to safeguard and secure the information we collect online.

Cookies:

We do not use cookies at this time.

Links to other websites:

Our website may contain links to other websites of interest. However, once you have used these links to leave our site, you should note that we do not have any control over that other website. Therefore, we cannot be responsible for the protection and privacy of any information which you provide whilst visiting such sites and such sites are not governed by this privacy statement. You should exercise caution and look at the privacy statement applicable to the website in question.

Controlling your personal information:

You may choose to restrict the collection or use of your personal information in the following ways:

• Whenever you are asked to fill in a form on the website, look for the box that you can click to indicate that you do not want the information to be used by anybody for direct marketing purposes. • If you have previously agreed to us using your personal information for direct marketing purposes, you may change your mind at any time by writing to or emailing us through our contact form.

We will not sell, distribute or lease your personal information to third parties unless we have your permission or are required by law to do so. We may use your personal information to send you promotional information about third parties which we think you may find interesting if you tell us that you wish this to happen.

You may request details of personal information which we hold about you under the Data Protection Act 1998. A small fee will be payable. If you would like a copy of the information held on you please write to:

KOL Health, Inc.. suite 303 /240 Wharncliffe Rd. N  N6H 4P2. London, Ontario, Canada.

If you believe that any information we are holding on you is incorrect or incomplete, please write to or email us as soon as possible, at the above address. We will promptly correct any information found to be incorrect.

 

More Articles
  • European Association for the Study of Diabetes

    No significant clinical trials on Diabetes released at the meeting. Many clinical trials in progress. New classes of drugs are available. Commonly DPP4 inhibitors, Januvia, Onglyza, Galvus and others to follow. Oral agents with no morbility and mortality data to date.
    There will be six available as early as 2013 in North America. All have same mode of action in the gut, but differ with dosing, price and side effects. Newer ones will have no renal issues at lower EGFR’s but generally those patients will be older and probably in the public reimbursement sector.

  • European Society of Cardiology

    conference 2011

    Most significant trial to be released was the ARISTOLE trial, concurrently published in N.E.J.M. Apixaban from BMS is a factor X inhibitor.

  • Cardiovascular disease

    Recently I attended the European Society of Hypertension meeting June 17-20 in Milan, Italy. This area tends to be a major source of clinical trials in HTN and cardiovascular disease.

  • Vitamin D3

    European Calcified Tissue Society and International Bone & Mineral

    Society

<< prev - page 1 of 1 - next >>

More Articles Questions Our Contributors

Site developer: In House Logic ©2009 - 2012 KOL Health Inc. Privacy Policy Mobile: m.kolhealth.com